JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB230371

Mz1, selectively degrades BRD4

Be the first to review this product! Submit a review

|

(1 Publication)

MW 1002.6 Da, Purity >98%. Cell penetrant PROTAC (Proteolysis Targeting Chimera) compound based on (+)-JQ1 (ab141498) tethered to a von Hippel-Lindau (VHL) ligand. Retains high affinity for BRD2, BRD3 and BRD4 bromodomains. Induces preferential degradation of BRD4 over BRD2 and BRD3 in HeLa cells.

View Alternative Names

2610203G15Rik, 2900045O07Rik, AF229032, AW108261, BRD4-NUT FUSION, BRD4-NUT fusion oncoprotein, BRD4_HUMAN, Bromodomain containing 4, Bromodomain-containing protein 4, CAP, CRBN_HUMAN, Cereblon, DDB p127 subunit, DDB1_HUMAN, DDBa, DKFZp781K0715, DNA damage-binding protein 1, DNA damage-binding protein a, Damage-specific DNA-binding protein 1, ELOB_HUMAN, ELOC_HUMAN, Elongin 15 kDa subunit, Elongin 18 kDa subunit, Elongin binding protein, Elongin-B, Elongin-C, G7 protein, HBV X-associated protein 1, HRCA 1, HUNK1, HUNKI, MCAP, MGC27358, MRT2A, Mitotic chromosome-associated protein, OTTHUMP00000209555, Protein G7, Protein HUNK1, Protein cereblon, Protein x 0001, RCA 1, RNA polymerase II transcription factor SIII p18 subunit, RNA polymerase II transcription factor SIII subunit B, RNA polymerase II transcription factor SIII subunit C, SIII, SIII p15, SIII p18, TCEB 1, TCEB 2, Transcription elongation factor B (SIII) polypeptide 1, Transcription elongation factor B (SIII) polypeptide 2, Transcription elongation factor B polypeptide 1, Transcription elongation factor B polypeptide 2, UV-DDB 1, UV-damaged DNA-binding factor, UV-damaged DNA-binding protein 1, VHL 1, VHLH, VHL_HUMAN, Von Hippel Lindau, Von Hippel Lindau tumor suppressor, E3 ubiquitin protein ligase, Von Hippel-Lindau disease tumor suppressor, X associated protein 1, XAP-1, XPCe, XPE, XPE-BF, XPE-binding factor, Xeroderma pigmentosum group E-complementing protein, chromosome associated protein, pVHL, piL, von Hippel Lindau syndrome, von Hippel Lindau tumor suppressor

1 Images
Chemical Structure - Mz1, selectively degrades BRD4 (AB230371)
  • Chemical Structure

Lab

Chemical Structure - Mz1, selectively degrades BRD4 (AB230371)

2D chemical structure image of ab230371, Mz1, selectively degrades BRD4

Key facts

CAS number

1797406-69-9

Purity

>98%

Form

Solid

form

Molecular weight

1002.6 Da

Molecular formula

C<sub>4</sub><sub>9</sub>H<sub>6</sub><sub>0</sub>ClN<sub>9</sub>O<sub>8</sub>S<sub>2</sub>

PubChem

122201421

Nature

Synthetic

Biochemical name

(2S,4R)-1-((S)-2-(tert-butyl)-17-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-4,16-dioxo-6,9,12-trioxa-3,15-diazaheptadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

Biological description

Cell penetrant PROTAC (Proteolysis Targeting Chimera) compound based on (+)-JQ1 (ab141498) tethered to a von Hippel-Lindau (VHL) ligand. Retains high affinity for BRD2, BRD3 and BRD4 bromodomains. Induces preferential degradation of BRD4 over BRD2 and BRD3 in HeLa cells.

Canonical smiles

CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)NCCOCCOCCOCC(=O)NC(C(=O)N4CC(CC4C(=O)NCC5=CC=C(C=C5)C6=C(N=CS6)C)O)C(C)(C)C)C7=CC=C(C=C7)Cl)C

Isomeric smiles

CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)NCCOCCOCCOCC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)NCC5=CC=C(C=C5)C6=C(N=CS6)C)O)C(C)(C)C)C7=CC=C(C=C7)Cl)C

InChi

InChI=1S/C49H60ClN9O8S2/c1-28-30(3)69-48-41(28)42(33-12-14-35(50)15-13-33)54-37(45-57-56-31(4)59(45)48)23-39(61)51-16-17-65-18-19-66-20-21-67-26-40(62)55-44(49(5,6)7)47(64)58-25-36(60)22-38(58)46(63)52-24-32-8-10-34(11-9-32)43-29(2)53-27-68-43/h8-15,27,36-38,44,60H,16-26H2,1-7H3,(H,51,61)(H,52,63)(H,55,62)/t36-,37+,38+,44-/m1/s1

InChiKey

PTAMRJLIOCHJMQ-PYNGZGNASA-N

IUPAC Name

(2S,4R)-1-[(2S)-2-[[2-[2-[2-[2-[[2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetyl]amino]ethoxy]ethoxy]ethoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

DDB1 is part of a complex known as the DDB1-CUL4-ROC1 E3 ubiquitin ligase complex which plays an important role in protein ubiquitination. It helps mark proteins for degradation by the proteasome. Von Hippel Lindau (VHL) is a tumor suppressor protein that interacts with Elongin B/C and forms part of the VCB-Cul2 complex which also targets hypoxia-inducible factors (HIFs) for degradation. Brd4 also called Bromodomain-containing protein 4 is a member of the BET family and weighs approximately 200 kDa. It is involved in transcriptional regulation and is highly expressed in neurons heart and testis. CRBN or Cereblon acts as a substrate receptor for the CRL4-CRBN E3 ubiquitin ligase complex binding to targeted proteins like IKZF1 and IKZF3 for ubiquitination and degradation.
Biological function summary

DDB1 Von Hippel Lindau BRD4 and CRBN participate in important cellular processes such as transcriptional regulation and protein degradation. BRD4 when bound to acetylated lysines on histones helps regulate gene expression by recruiting transcriptional machinery to target genes. MZ1 and JQ1 specific small-molecule inhibitors modulate BRD4 function. In various complexes like the Elongin BC complex Elongin B and C stabilize these functions participating in elongation and transcription regulation processes. CRBN modulates the function of specific target proteins by promoting their ubiquitination and subsequent proteasomal degradation.

Pathways

These proteins integrate into the ubiquitin-proteasome system and transcriptional regulatory pathways. DDB1 collaborates with CUL4A in DNA damage repair and cell cycle control. VHL associates within the hypoxia signaling pathway by mediating the degradation of HIF1α under normoxic conditions. This degradation prevents uncontrolled cell growth and angiogenesis. On the other hand BRD4 takes part in the transcription elongation process and interacts with MZ-1 a potent PROTAC that alters chromatin structure to influence gene expression.

These proteins connect to cancer and neurodegenerative diseases. Mutations in the VHL gene lead to Von Hippel-Lindau disease a hereditary cancer syndrome. This deleterious effect occurs due to the accumulation of hypoxia-inducible factors from impaired VHL function. BRD4 attracts researchers' interest due to its involvement in diverse cancers as it regulates MYC oncogene activity and cell cycle progression. Pharmaceuticals targeting BRD4 such as BET inhibitors show promise in cancer therapies. Similarly altered CRBN activity is linked to cerebellar ataxia demonstrating its relevance in neurological conditions.

Product protocols

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Cell death & disease 13:921 PubMed36333293

2022

EGFR-induced suppression of HPV E6/E7 is mediated by microRNA-9-5p silencing of BRD4 protein in HPV-positive head and neck squamous cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Danupon Nantajit,Luana Presta,Thomas Sauter,Mahvash Tavassoli
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com